NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is a publicly traded Healthcare sector company. As of July 5, 2026, NAMS trades at $34.83 with a market cap of $4.07B and a P/E ratio of -19.46. NAMS moved -1.08% today. Year to date, NAMS is +0.26%; over the trailing twelve months it is +83.70%. Its 52-week range spans $14.06 to $42.21. Analyst consensus is strong buy with an average price target of $47.86. Rallies surfaces NAMS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NewAmsterdam Pharma to Present Nine Obicetrapib Abstracts at NLA 2026 Sessions: NewAmsterdam Pharma will present nine abstracts on obicetrapib’s safety, efficacy, kidney preservation and pharmacokinetics at the NLA 2026 Scientific Sessions in Chicago on June 12. The company randomized over 9,500 patients in the Phase 3 PREVAIL cardiovascular outcomes trial and granted Europe commercialization rights to Menarini Group.
| Metric | Value |
|---|---|
| Price | $34.83 |
| Market Cap | $4.07B |
| P/E Ratio | -19.46 |
| EPS | $-1.79 |
| Dividend Yield | 0.00% |
| 52-Week High | $42.21 |
| 52-Week Low | $14.06 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $22.57M |
| Net Income | $-212.73M |
| Gross Margin | 0.00% |
10 analysts cover NAMS: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $47.86.